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GUEST EDITORIAL
The endocrine prevention of breast cancer
I.S. Fentiman
ICRF Clinical Oncology Unit, Guy's Hospital, London SE] 9RT, UK.
The evolution of breast cancer probably comprises a series of carcinogenic hits with ensuing promotion
by the normal endocrine milieu (Moolgavkar et al., 1980). Despite a plethora of hypotheses on the
nature of the inducing stimuli, understanding has not advanced beyond the black box stage. In the
absence of tangible causes for an identified chain of somatic mutations which could be avoided or
minimised, attention has focused on the subsequent hormonal modulation of transformed malignant
cells. Both animal and human data suggest that early oophorectomy can inhibit phenotypic expression
of malignancy (Miller & Bulbrook, 1980). The central role of ovarian hormones is powerfully supported
by the age incidence curves of human breast cancer where the peri-menopausal inflexion suggests that
the menopause itself prevents many women from developing clinical evidence of malignancy. For these
various reasons the case for the endocrine prevention of breast cancer by blockade or ablation of
ovarian steroid hormones has been made.
For prevention to dent national incidence and mortality statistics, several criteria need to be met.
First, a regimen must be available which is simple and sufliciently non-toxic to be administered to large
numbers of ostensibly normal women. Second, the one in 12 women who will develop breast cancer
need to be identified. Third, the effectiveness of the agent needs to be confirmed in prospective trials.
Fourth, such a scheme of prevention needs to be affordable for countries with limited health budgets.
Finally, since it is unlikely that any hormonal therapy will produce absolute protection, there will be
some individuals who will develop breast cancer while on treatment. If such cancers are more aggressive
and lead to an increased mortality rate, this could abolish any benefit gained by other individuals in the
group.
Since Cuzick et al. (1986) proposed the use of tamoxifen as a preventive agent, heated discussion has
ensued. In part this stemmed from the oestrogen antagonist effects of the drug, with theoretical risks of
bone demineralisation and changes in lipoprotein profile with increased risk of coronary heart disease. It
would be pointless to try and prevent breast cancer and in so doing increase deaths from myocardial
infarction and complications of pathological fractures. This particular argument can now be dismissed.
A large body of work has shown consistently in women as well as rodents that tamoxifen is a partial
oestrogen agonist, inducing elevation of sex hormone binding globulin, cortisol binding globulin,
reduction of low density lipoproteins and elevation of high density lipoprotein (Groom & Griffiths,
1976; Sherman et al., 1979; Sakai et al., 1978; Rossner & Wallgren, 1984; Caleffi et al., 1988).
Furthermore, sequential studies of bone mineral content have shown no loss in women given tamoxifen
(Fentiman et al., 1988, Powles et al., 1989).
As these data have become accepted, so the direction of attack has veered with the oestrogen agonist
effect being regarded as a potential disadvantage because it might lead to an increase in oestrogen
related cancers of endometrium and liver. The latter is almost certainly a very small risk in humans, but
the former may represent a significant clinical problem when tamoxifen is given to women who have not
had a hysterectomy. The most recent report of the Swedish trial in which patients were given long-term
adjuvant tamoxifen has indicated that after a median follow-up of 4.5 years, that 1.4% of the treated
group developed endometrial carcinoma compared with only 0.2% of the controls (Fornander et al.,
1989). However, in the Scottish trial after a follow-up of 4-10 years there was no increase in
endometrial cancers in the tamoxifen treated group who received 20mg daily rather than 40mg which
was given to the Swedish patients (Stewart & Knight, 1989). The Swedish trial does provide supportive
evidence for the value of tamoxifen as a preventive agent. There was a significant reduction in new
primary breast cancers in the treated group (18 versus 30). Of course it could be argued that this 60%
reduction is merely a short-term effect with prolongation of the pre-clinical phase of contralateral
carcinomas. Nevertheless, this evidence of preventive activity cannot be dismissed.
The lack of toxicity of tamoxifen has been a consistent feature of adjuvant trials but these have
largely comprised post-menopausal patients. However, studies of premenopausal women with mastalgia
have also shown that tamoxifen was well tolerated by younger women who did not have breast cancer
(Fentiman et al., 1986; Powles et al., 1989). The incidence of side-effects, particularly hot flushes and
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menstrual irregularity, can be reduced further when a dosage of 10mg rather than 20mg is given, and
this is equally effective for the treatment of mastalgia (Fentiman, 1988). Might this also be true for the
prevention of breast cancer?
Powles et al. (1989) have successfully conducted a difficult pilot study for the use of tamoxifen in
women with a family history of breast cancer. This important work underwent a set-back with the mid-
study release of rat-toxicity data indicating a high incidence of hepatocellular carcinomas after
administration of 50-100 times the dosage given to women. It took a paper in the Lancet defending its
use for benign indications (followed by no adverse correspondence) together with a re-writing of the
protocol and consent requirements to allow accrual to the trial to be re-started (Fentiman & Powles,
1987). This feasibility study has shown the acceptability of and compliance with tamoxifen administ-
ration in normal women with a first degree family history with over 80% of patients complying with
treatment.
It has been estimated that 5% of breast cancers are familial (Lynch et al., 1984). Taking the data of
Powles et al., there was a 47% acceptance by eligible women. A further 7% stopped taking either
tamoxifen or placebo because of side-effects. Thus if 40% of high risk women will take the drug and
assuming a 50% reduction in incidence, then one in five of the high risk group might be prevented from
developing breast cancer. Overall, therefore, a 1% reduction in breast cancer incidence might be effected
by this approach, using family history as a risk indicator, assuming that oestrogens are responsible for
the early presentation of familial breast cancers.
The identification of a high-risk group is one of the greater obstacles to the wider application of
prevention, since the treatment of entire populations would be prohibitively expensive. At present,
family history is one of the few reliable risk indicators.
The rare variant, lobular carcinoma in situ (LCIS), carries a one in three lifetime risk of subsequent
infiltrating carcinoma. The EORTC have set up a trial for such cases in which patients are randomly
allocated to the standard treatment (close observation), or to receive tamoxifen 20mg daily for 5 years
(Fentiman, 1988). The rarity of LCIS mandates a multi-centre study, but even so it has been very
difficult to get adequate accrual for the trial. Other risk factors which could be considered include
histologically confirmed atypical ductal or lobular hyperplasia, where a 3-4-fold increase in risk is
present (Dupont & Page, 1985). Another possibility as a marker is the percentage of free oestradiol
(Moore et al., 1986). However, this remains contentious. Although it emerged as a risk indicator in
some case-control studies, it has never been used prospectively, due in part to the technical difficulties
of the assay. Instead of directly measuring levels of available oestradiol another approach is to use a
biological marker of oestrogen activity, namely bone mineral content. At present this is being evaluated
prospectively in a study in Guernsey.
Thus despite being a minority risk indicator for a disease which may have a different aetiology and
natural history, family history is the most easily ascertainable marker of risk that could be used to
determine eligibility for multi-centre prevention trials.
A major merit of tamoxifen is its simplicity of administration. Pike et al. (1989) propose a more
complex approach to prevention. They suggest the total ablation of ovarian function with LHRH
agonist followed by the controlled replacement of oestrogen, possibly with additional intermittent
progestin, the latter to protect the uterus. This strategy pre-supposes that there are different thresholds
of response to oestrogen stimulation in breast epithelium, hepatocytes and osteoblasts. If this were not
the case, patients would be risking bone demineralisation, altered hepatic synthesis of lipoproteins or
breast cancer promotion. Who can say? It will certainly be necessary to conduct a similar study to that
of Powles et al. before a larger trial of prevention can be carried out. Financial reasons should not
inhibit trials of new treatment but it has to be noted that the cost of tamoxifen treatment for one
patient over one year is £112 whereas the cost of LHRH agonists (without progestin) is £1,368. The
merit of LHRH agonists is their reversibility. However, if ovarian ablation is to be seriously considered
for prevention it may be better to effect permanent suppression by external irradiation.
There are now several compelling reasons to mount a large-scale trial to evaluate tamoxifen as a
preventive agent. For the sake of simplicity it might comprise a comparison of 20mg tamoxifen daily
with placebo, given for probably a minimum of 10 years. Opportunities for prevention trials will be
limited, and it would be interesting to use a factorial 2 x 2 approach and examine the respective roles of
tamoxifen and progestin. No feasibility study would be necessary for progestin which has been in wide
use as an oral contraceptive in young women with no major untoward side-effects. However, a
pragmatic approach is necessary and it is unlikely that this would be widely accepted. Any prevention
study will have to be multicentric and would almost certainly require funding from more than one of
the major cancer charities. It will be expensive and there are many logistic problems to be resolved
including the formulation of the agent(s) and placebo. Nevertheless, there are now no convincing
arguments for not starting such a trial. The ground has been well prepared; now is the time to sow the
seeds of prevention.14 I.S. FENTIMAN
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